George M Milne Jr sold $831k of AMLX
director at Amylyx Pharmaceuticals, Inc.. 30,000 shares at an average of $27.70, traded Oct 5, 2026, filed Oct 7, 2026.
Score components
- +15RoleDirector
- +23Trade size$831k at market
- 0Share of holdings soldSold 3.7% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-416950, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -30,000 | $27.70 | $831k | 782,881 | 5 d ago |
Related signals
Other insiders at Amylyx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $980k 30,464 shares | -1% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $981k 30,464 shares | -1% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $310k 9,536 shares | -5% | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $350k 10,810 shares | -4% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $325k 10,028 shares | -3% | |
| 13Weak | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $246k 30,000 shares | -16% | |
| 48Moderate | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $74k 21,490 shares | -1% | |
| 48Moderate | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $74k 21,490 shares | -1% | |
| 35Weak | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $32k 9,192 shares | -5% | |
| 36Weak | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $43k 12,425 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.